drugset / Trial / NCT00002081

Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease

NCT00002081 ↗

Completed Hoffmann-La Roche
Open-labelTreatment

Summary

To provide zalcitabine ( dideoxycytidine; ddC ) for use with zidovudine ( AZT ) in patients with advanced HIV infection. To observe serious toxicities in this population.

Timeline

Start
—
Primary completion
—
Completion
—

Publications

  • Background Walker M, Moyle GJ, Harris R, Warburg M. Safety and efficacy of zalcitabine (ddC) and zidovudine (ZDV) combination in HIV-positive persons with CD4 cell counts less than or equal to 300/mm3: an international open label evaluation (Roche study M50002). Int Conf AIDS. 1996 Jul 7-12;11(1):77 (abstract no MoB1129)

Drugs

EvaluationDrugModalityDoseRoute
Subject Zalcitabine Small molecule — Oral
Subject Zidovudine Small molecule — Oral